Showing posts with label News. Show all posts
Showing posts with label News. Show all posts

Sunday, 28 May 2017

Zika virus in India

Zika virus infection – India

On 15 May 2017, the Ministry of Health and Family Welfare-Government of India (MoHFW) reported three laboratory-confirmed cases of Zika virus disease in Bapunagar area, Ahmedabad District, Gujarat, State, India.
The routine laboratory surveillance detected a laboratory-confirmed case of Zika virus disease through RT-PCR test at B.J. Medical College, Ahmedabad, Gujarat. The etiology of this case has been further confirmed through a positive RT-PCR test and sequencing at the national reference laboratory, National Institute of Virology (NIV), Pune on 4 January 2017 (case 2, below). Two additional cases (case 1 and case 3), have then been identified through the Acute Febrile Illness (AFI) and the Antenatal clinic (ANC) surveillance. The cases are reported below in chronological order:
Case 1: During the Acute Febrile Illness (AFI) surveillance between 10 to 16 February 2016, a total of 93 blood samples were collected at BJ Medical College (BJMC), Ahmedabad, Gujarat State. One sample from a 64-year-old male presenting with febrile illness of 8 days’ duration (negative for dengue infection) was found to be positive for Zika virus at BJMC, Ahmedabad. This is the first Zika positive case reported through AFI surveillance at BJMC, Ahmedabad, Gujarat State.
Case 2: A 34-year-old female, delivered a clinically well baby at BJMC in Ahmedabad on 9 November 2016. During her hospital stay, she developed a low grade fever after delivery. No history of fever during pregnancy and no history of travel for the past three months was reported. A sample from the patient was referred to the Viral Research & Diagnostic Laboratory (VRDL) at the BJMC for dengue testing and thereafter found to be positive for Zika virus. She was discharged after one week (on 16 November 2016). The sample was re-confirmed as Zika virus positive by RT-PCR and sequencing at NIV, Pune.
Case 3: During the Antenatal clinic (ANC) surveillance between 6 and 12 January 2017, a total of 111 blood samples were collected at BJMC. One sample from a 22-year-old pregnant female in her 37th week of pregnancy has been tested positive for Zika virus disease.
Public health response
National Guidelines and Action Plan on Zika virus disease have been shared with the States to prevent an outbreak of Zika virus disease and containment of spread in case of any outbreak.
An Inter-Ministerial Task Force has been set up under the Chairmanship of Secretary (Health and Family Welfare) together with Secretary (Bio-Technology), and Secretary (Department of Health Research). The Joint Monitoring Group, a technical group tasked to monitor emerging and re-emerging diseases is regularly reviewing the global situation on Zika virus disease.
All the international airports and ports have displayed information for travellers on Zika virus disease.
The airport health officers along with airport organizations, National Centre for Disease Control, and the National Vector Borne Disease Control Programme are monitoring appropriate vector control measures in airport premises.
The Integrated Disease Surveillance Programme (IDSP) is tracking for clustering of acute febrile illness in the community.
In addition to National Institute of Virology, Pune, and NCDC in Delhi, 25 laboratories have also been strengthened by Indian Council of Medical Research for laboratory diagnosis. In addition, 3 entomological laboratories are conducting Zika virus testing on mosquito samples.
The Indian Council of Medical Research (ICMR) has tested 34 233 human samples and 12 647 mosquito samples for the presence of Zika virus. Among those, close to 500 mosquitos samples were collected from Bapunagar area, Ahmedabad District, in Gujarat, and were found negative for Zika.
The Rashtriya Bal Swasthya Karyakram (RBSK) is monitoring microcephaly from 55 sentinel sites. As of now, no increase in number of cases or clustering of microcephaly has been reported from centers.

Friday, 22 July 2016

Cervical Cancer and Human Papillomavirus

Cervical Cancer and Human Papillomavirus

Reading through The Philippine Star, I bumped into an advertisement which presents a husband lying in bed and trying to feel the presence of his deceased wife. What makes this interesting is the question flashed below which goes Naisip mo na ba kung gaano kasakit matulog at gumising na mga-isa?. Apparently, this seeks to inform readers that a woman has an eighty percent chance of already being infected with human papillomavirus (HPV) when she reaches fifty and that there are ten women who die of cervical cancer hence, ten new widowers everyday.

This advertisement brought me back to an article entitled A survivor’s battle with cervical cancer by Annie A. Jambora which was released last August fifth in Philippine Daily Inquirer. This highlights the experience of Josefina de la Cruz with cervical cancer, country’s second leading cause of death among Filipino women. Other than her menstrual period which takes much longer than usual, sometimes going for full ten days, she was feeling fine. In August 2001, exactly ten years after her mother succumbed to the same disease, she was diagnosed with multiple myoma. 

                           

Although the diagnosis is not a life-threatening condition, she nevertheless pushed through with all the necessary medical procedures. However, it was just last year when she figured out that the cancer was actually caused by HPV which she, unknowingly, had acquired from her husband.

Cervical Cancer

The Harvard Guide to Women’s Health defines cervical cancer as a disease that develops gradually starting with abnormal cell changes called preinvasive lesions (also called low-grade squamous intraepithelial lesions, or SIL; or dysplasia). These sometimes revert to normal cells. Nevertheless, these cell changes are considered a precancerous condition. In time (sometimes a full decade), some precancerous cells may develop into localized cancer, called carcinoma in situ, which affects the outer surface of the cervix (Carlson, Eisenstat, Ziporyn, 1996, p. 130).

World Health Organization states, in its website, that all cervical cancer cases (99%) are linked to genital infection with HPV, which is the most common viral infection of the reproductive tract.

Human Papillomavirus (HPV)

Cervical cancer, human papillomavirus (HPV), and HVP vaccines-Key points for policy makers and health professionals provides main points on this virus.

 HPVs are a family of viruses that are extremely common worldwide. There are more than 100 types.
 They are deoxyribonucleic acid (DNA) viruses that infect skin or mucosal cells.
 At least 13 of these types are oncogenic (cancer-causing).
 HPV is estimated to cause
-100% of cancer cases,
-90% of anal cancer cases,
-40% of cases of cancers of the external genitalia (vulva, vagina and penis),
-at least 12% of oropharyngeal cancer cases, and
-at least 3% of oral cancer cases.
 HPV types 16 and 18 cause approximately 70% of all cervical cancers worldwide.
 Almost 500 000 cases of cervical cancer and 274 000 cervical cancer deaths occurred in 2002.
 About 80% of cervical cancer deaths occur in developing countries.
                           
In the article which was mentioned earlier, it is stated that HPV, affecting both men and women, can be acquired only through skin contact. Men are generally spared from the deadly virus and only serve as carriers even if they use condoms. These do not protect a woman from contacting the said virus since the scrotum is still exposed.

It is wonderful knowing that newsprint media have started realizing the importance of writing on cervical cancer and human papillomavirus (HPV) as one of its causes. Untold stories of women, we can now finally conclude, are beginning to be told.
Source : one of my Friend 

Wednesday, 20 July 2016

FDA approves first intraocular lens with extended range of vision for cataract patients

FDA approves first intraocular lens with extended range of vision for cataract patients


The U.S. Food and Drug Administration today approved the first intraocular lens (IOL) that provides cataract patients with an extended depth-of-focus, which helps improve their sharpness of vision (visual acuity) at near, intermediate and far distances.
Cataracts are a common eye condition where the natural lens becomes clouded, impairing a patient’s vision. According to the National Eye Institute, more than 20 percent of Americans will have cataracts by the age of 65, and the prevalence increases with age. In cataract surgery, the clouded natural lens is removed and replaced with an IOL.
“While IOLs have been the mainstay of cataract treatment for many years, we continue to see advances in the technology,” said Malvina Eydelman, M.D., director of the Division of Ophthalmic and Ear, Nose and Throat Devices in the FDA’s Center for Devices and Radiological Health. “The Tecnis Symfony Extended Range of Vision IOL provides a new option for patients that may result in better vision across a broader range of distances.”
Traditional monofocal IOLs have been limited to improving distance vision. The Tecnis Symfony IOL improves visual acuity at close, intermediate and far ranges and, therefore, may reduce the need for patients to wear contact lenses or glasses after cataract surgery.
The approval is based on a review of results from a randomized clinical trial comparing 148 cataract patients implanted with the Tecnis Symfony IOL to 151 cataract patients implanted with a monofocal IOL. The study evaluated visual acuity at near, intermediate and far ranges; contrast sensitivity (the ability to distinguish small differences between light and dark); and adverse events for six months after implantation. Of the patients implanted with the Tecnis Symfony IOL, 77 percent had good vision (20/25), without glasses at intermediate distances, compared to 34 percent of those with the monofocal IOL. For near distances, patients with the Tecnis Symfony IOL were able to read two additional, progressively smaller lines on a standard eye chart than those with the monofocal IOL. Both sets of patients had comparable results for good distance vision.
Patients implanted with the Tecnis Symfony IOL may experience worsening of or blurred vision, bleeding or infection. The device may cause reduced contrast sensitivity that becomes worse under poor visibility conditions such as dim light or fog. Some patients may experience visual halos, glare or starbursts. The device is not intended for use on patients who have had previous trauma to their eye.
The Tecnis Symfony IOL is also available in four toric models, which are indicated for the reduction of residual refractive astigmatism or imperfections in the curvature of the eye.
The Tecnis Symfony Extended Range of Vision IOL is manufactured by Abbott Medical Optics, Inc. of Santa Ana, California.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, and dietary supplements, for products that give off electronic radiation, and for regulating tobacco products.

Tuesday, 19 July 2016

lifitegrast ophthalmic solution




The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 (LFA-1) antagonist, approved by the FDA for dry eye disease.
“Normal tear production is needed for clear vision and eye health,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “This approval will provide a new treatment option for patients with dry eye disease.”
Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. The chance of experiencing dry eye increases with age, affecting approximately five percent of the adult population age 30-40 and 10 to 15 percent of adults over age 65, and is more common among women. When severe and left untreated, this condition can lead to pain, ulcers or scars on the part of the eye called the cornea. Dry eye can make it more difficult to perform some activities, such as using a computer or reading for an extended period of time, and it can decrease tolerance for dry environments, such as the air inside an airplane.
The safety and efficacy of Xiidra was assessed in over a thousand patients, in four separate, randomized, controlled studies. These studies included patients 19–97 years of age, of which the majority were female (76 percent). Patients were randomized equally to receive either Xiidra eyedrops or placebo eyedrops, which were used twice a day for twelve weeks. The studies found that groups treated with Xiidra demonstrated more improvement in both the signs and the symptoms of eye dryness than the groups treated with placebo.
The most common side effects of Xiidra include eye irritation, discomfort or blurred vision and an unusual taste sensation (dysgeusia).
Dry eye disease does not routinely occur in children. Safety and efficacy in pediatric patients below the age of 17 years has not been studied.

Xiidra is manufactured by Shire US Inc., of Lexington, Massachusetts.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Wednesday, 6 July 2016

2015-2016 Influenza Season: Availability of Antivirals

  • Tamiflu (oseltamivir phosphate) Oral Suspension
    • No current shortage.
    • If there is difficulty locating commercial Tamiflu for Oral Suspension, FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. This compounded suspension should not be used for convenience or when the FDA-approved Tamiflu for oral suspension is commercially available.  Please see information for healthcare professionals regarding compounding an oral suspension from Tamiflu 75 mg capsules at: Tamiflu: Emergency Compounding
  • Tamiflu (oseltamivir phosphate) 75 mg Capsules
    • No current shortage.
  • Tamiflu (oseltamivir phosphate) 45 mg Capsules
    • No current shortage.
    • Pediatric patients can be dosed correctly with the 30 mg and 45 mg capsules.
  • Tamiflu (oseltamivir phosphate) 30 mg Capsules
    • No current shortage.
    • Pediatric patients can be dosed correctly with the 30 mg and 45 mg capsules.
  • Relenza (zanamivir) Inhalation Powder
    • No current shortage.
  • Rapivab (peramivir) Injection
    • No current shortage
  • Additional Resources